C. Zanna

发表

IntraoperativeAvidination for RadionuclideTherapy : AProspective New Development toAccelerate Radiotherapy in Breast Cancer

A. Luini, U. Veronesi, L. Travaini, 2007 .

Intraoperative Avidination for Radionuclide Therapy: A Prospective New Development to Accelerate Radiotherapy in Breast Cancer

A. Luini, U. Veronesi, L. Travaini, 2007, Clinical Cancer Research.

Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity.

G. Cavaletti, C. Zanna, 2002, European journal of cancer.

Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.

H. Nauwelaerts, C. Nutting, B. Burtness, 2022, Future oncology.

Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study

David C. Smith, H. Hurwitz, H. Pitot, 2015, Cancer Chemotherapy and Pharmacology.

The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma.

J. Bourhis, G. Vuagniaux, N. Wiedemann, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale

A. Lissoni, G. Cavaletti, N. Colombo, 2003, Neurology.

First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results.

David C. Smith, H. Hurwitz, H. Pitot, 2014 .

FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma.

Rachel B. Keller, W. Hahn, M. Meyerson, 2021, Cancer discovery.

The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: comparison with the National Cancer Institute‐Common Toxicity Scale

A. Caraceni, A. Lissoni, G. Cavaletti, 2007, Journal of the peripheral nervous system : JPNS.

Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy.

A. Lissoni, G. Cavaletti, N. Colombo, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology.

K. Flaherty, F. Meric-Bernstam, J. Tabernero, 2019, Journal of Clinical Oncology.

AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results

K. Flaherty, M. Voss, G. Iyer, 2019, Hepatobiliary surgery and nutrition.

Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine.

A. Caraceni, L. Gianni, G. Bianchi, 2005, European journal of cancer.

A Pilot Study on the Effect of Acetyl-L-Carnitine in Paclitaxel-And Cisplatin-Induced Peripheral Neuropathy

L. Crinò, E. Cortesi, A. Maestri, 2005, Tumori.

Ketanserin Interactions with Nifedipine and Captopril: Two Italian Cross over Trials

A. Salvetti, A. Bossini, C. Veroli, 1990 .

Acetyl-L-Carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties.

M. Miloso, G. Nicolini, C. Pisano, 2005, Anticancer research.

Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor.

M. Voss, R. Heist, J. Supko, 2015 .

Ketanserin Alone and in Combination with Enalapril in the Treatment of Essential Hypertension: Assessment of the Haemodynamic Effects

V. Palmieri, M. Galderisi, O. de Divitiis, 1993, The Journal of international medical research.

Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetcs/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer.

F. Brichory, P. Rochaix, S. Temam, 2021, Clinical and translational science.

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.

N. Magné, B. Chauffert, J. Bourhis, 2020, The Lancet. Oncology.

Abstract C2: Clinical safety, pharmacokinetics and early evidence of activity of the oral IAPs inhibitor Debio 1143 in combination with carboplatin and paclitaxel: a phase Ib study

I. Ray-Coquard, P. Fumoleau, M. Sablin, 2015 .

Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.

R. Larson, J. Dipersio, M. Tallman, 2015, Clinical lymphoma, myeloma & leukemia.

Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.

M. Zucchetti, J. Baselga, C. Sessa, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract 5441: Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care agents in human lung cancer models

Shaomeng Wang, C. G. Langdon, J. Platt, 2014 .

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

A. Iafrate, K. Flaherty, J. Baselga, 2019, Clinical Cancer Research.

Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC).

K. Flaherty, J. Baselga, M. Voss, 2018 .

Chemotherapy‐induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale

Guido Cavaletti, G. Cavaletti, P. Alberti, 2011, Journal of the peripheral nervous system : JPNS.

Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model

P. Fumoleau, F. Brunotte, J. Vrigneaud, 2018, Contrast media & molecular imaging.

Ketanserin and captopril interaction in the treatment of essential hypertensives

A. Salvetti, C. Zanna, G. Lavezzaro, 2004, Cardiovascular Drugs and Therapy.

TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer.

H. Nauwelaerts, C. Nutting, B. Burtness, 2021 .

IART: intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation.

A. Luini, U. Veronesi, M. Ferrari, 2007, Breast.

Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.

K. Flaherty, J. Baselga, M. Voss, 2017 .

Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.

K. Flaherty, I. Mellinghoff, G. Iyer, 2020 .

ANTIHYPERTENSIVE AND METABOLIC EFFECTS OF KETANSERIN IN PATIENTS WITH HYPERTENSION AND IMPAIRED GLUCOSE TOLERANCE : A DOUBLE-BLIND RANDOMIZED, PLACEBO -CONTROLLED, CROSSOVER STUDY

G. Noto, A. Rappelli, E. Espinosa, 1991 .

Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

J. Bourhis, Y. Tao, V. Calugaru, 2020, Clinical Cancer Research.